Strategic Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.2M Sell
44,492
-1,638
-4% -$352K 2.45% 11
2026
Q1
$10M Sell
46,130
-1,033
-2% -$229K 1.67% 11
2025
Q4
$10.8M Sell
47,163
-1,113
-2% -$254K 1.69% 12
2025
Q3
$11.2M Buy
48,276
+257
+0.5% +$52.3K 1.8% 12
2025
Q2
$8.91M Sell
48,019
-2,314
-5% -$430K 1.75% 12
2025
Q1
$10.5M Sell
50,333
-1,397
-3% -$272K 2.03% 10
2024
Q4
$9.19M Sell
51,730
-2,552
-5% -$469K 1.66% 14
2024
Q3
$10.7M Sell
54,282
-4,784
-8% -$893K 2% 9
2024
Q2
$10.1M Sell
59,066
-5,089
-8% -$843K 1.97% 9
2024
Q1
$11.7M Buy
64,155
+3,628
+6% +$625K 2.3% 9
2023
Q4
$9.38M Sell
60,527
-17,929
-23% -$2.61M 1.78% 13
2023
Q3
$11.7M Buy
78,456
+1,615
+2% +$237K 2.31% 11
2023
Q2
$10.4M Sell
76,841
-820
-1% -$120K 1.97% 12
2023
Q1
$12.4M Buy
77,661
+998
+1% +$153K 2.51% 10
2022
Q4
$12.4M Sell
76,663
-3,042
-4% -$466K 2.76% 8
2022
Q3
$10.7M Sell
79,705
-41
-0.1% -$5.88K 2.37% 10
2022
Q2
$12.2M Sell
79,746
-1,301
-2% -$199K 2.55% 9
2022
Q1
$13.1M Sell
81,047
-2,887
-3% -$419K 2.28% 10
2021
Q4
$11.4M Buy
83,934
+5,973
+8% +$706K 1.62% 13
2021
Q3
$8.41M Buy
77,961
+14,712
+23% +$1.68M 1.81% 12
2021
Q2
$7.12M Buy
63,249
+626
+1% +$70.5K 1.85% 11
2021
Q1
$6.78M Buy
62,623
+7,730
+14% +$827K 1.97% 11
2020
Q4
$5.86M Buy
54,893
+3,824
+7% +$367K 1.69% 16
2020
Q3
$4.49M Buy
51,069
+443
+0.9% +$41.7K 1.51% 17
2020
Q2
$4.95M Buy
50,626
+22,975
+83% +$2.02M 1.85% 15
2020
Q1
$2.17M Buy
27,651
+6,767
+32% +$576K 0.95% 24
2019
Q4
$1.85M Buy
20,884
+4,662
+29% +$387K 0.64% 44
2019
Q3
$1.23M Buy
16,222
+9,266
+133% +$635K 0.46% 58
2019
Q2
$505K Sell
6,956
-238
-3% -$18.7K 0.19% 94
2019
Q1
$580K Sell
7,194
-10,692
-60% -$875K 0.22% 92
2018
Q4
$1.65M Sell
17,886
-673
-4% -$59.2K 0.72% 36
2018
Q3
$1.75M Sell
18,559
-1,877
-9% -$178K 0.64% 43
2018
Q2
$1.89M Sell
20,436
-25,784
-56% -$2.52M 0.76% 36
2018
Q1
$4.38M Buy
46,220
+66
+0.1% +$7.25K 1.81% 15
2017
Q4
$4.46M Sell
46,154
-791
-2% -$74.5K 1.82% 16
2017
Q3
$4.17M Buy
46,945
+416
+0.9% +$31.7K 1.81% 14
2017
Q2
$3.37M Sell
46,529
-566
-1% -$38.1K 1.54% 19
2017
Q1
$3.07M Buy
47,095
+436
+0.9% +$27.4K 1.45% 21
2016
Q4
$2.92M Buy
46,659
+249
+0.5% +$15.2K 1.53% 16
2016
Q3
$2.93M Buy
46,410
+432
+0.9% +$28K 1.64% 15
2016
Q2
$2.85M Sell
45,978
-4,126
-8% -$251K 1.64% 14
2016
Q1
$2.86M Sell
50,104
-223
-0.4% -$12.4K 1.63% 12
2015
Q4
$2.98M Sell
50,327
-83
-0.2% -$4.78K 1.95% 13
2015
Q3
$2.74M Buy
50,410
+42
+0.1% +$2.73K 1.9% 14
2015
Q2
$3.38M Buy
50,368
+35,562
+240% +$2.32M 2.16% 10
2015
Q1
$836K Buy
14,806
+96
+0.7% +$5.8K 0.54% 62
2014
Q4
$963K Buy
14,710
+55
+0.4% +$3.47K 0.63% 57
2014
Q3
$846K Sell
14,655
-151
-1% -$8.38K 0.56% 64
2014
Q2
$836K Buy
14,806
+3,232
+28% +$170K 0.53% 62
2014
Q1
$595K Sell
11,574
-150
-1% -$7.58K 0.4% 80
2013
Q4
$619K Sell
11,724
-266
-2% -$13.1K 0.42% 80
2013
Q3
$536K Sell
11,990
-1,397
-10% -$61.9K 0.44% 73
2013
Q2
$557K Buy
+13,387
New +$585K 0.5% 65

Other funds holding ABBV

Strategic Advisors's ABBV Position: Q2 2026 in Review

Strategic Advisors reduced its AbbVie (ABBV) stake by 3.6% in Q2 2026, selling an estimated $352K and leaving 44,492 shares worth $11.2M. The position accounts for 2.45% of the portfolio, ranked #11.

Strategic Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $13.1M in Q1 2022. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Strategic Advisors held 44,492 shares of AbbVie worth $11.2M as of Q2 2026.
  • Strategic Advisors sold 1,638 AbbVie shares in Q2 2026, an estimated $352K.
  • AbbVie made up 2.45% of Strategic Advisors's portfolio in Q2 2026, its #11 holding.
  • Strategic Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Strategic Advisors's AbbVie position peaked at $13.1M in Q1 2022.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Strategic Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.